EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility



In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility



Journal of Antimicrobial ChemoTherapy 46(6): 905-908



Two ketolides, telithromycin and HMR 3004, were evaluated for their in vitro activity against erythromycin-susceptible and -resistant strains of Streptococcus pyogenes and Streptococcus pneumoniae. On the basis of their resistance to macrolide, lincosamide and streptogramin (MLS) antibiotics, erythromycin-resistant test strains were assigned to the constitutive resistance (cMLS) phenotype, the inducible resistance (iMLS) phenotype or the M phenotype. iMLS S. pyogenes strains were further subdivided into the three recently described subtypes iMLS-A, -B and -C. Telithromycin and HMR 3004 were uniformly and highly active against pneumococci (regardless of their susceptibility or resistance to erythromycin and/or penicillin), erythromycin-susceptible S. pyogenes and erythromycin-resistant S. pyogenes strains of the M phenotype (in which resistance is mediated by an efflux system) or iMLS-B or -C phenotype (in which resistance is mediated by a methylase encoded by the ermTR gene). Both ketolides were less active against erythromycin-resistant S. pyogenes strains with the cMLS phenotype or the iMLS-A subtype (where resistance is mediated by a methylase encoded by the ermAM gene), these strains ranging in phenotype from the upper limits of susceptibility to low-level resistant.

(PDF emailed within 0-6 h: $19.90)

Accession: 010811747

Download citation: RISBibTeXText

PMID: 11102408

DOI: 10.1093/jac/46.6.905



Related references

In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. Letters in Applied Microbiology 47(4): 309-314, 2009

In vitro compared activity of telithromycin and azithromycin against northwest Italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility. Letters in Applied Microbiology 47(4): 309-314, 2008

In vitro activities of the ketolides ABT-773 and telithromycin and of three macrolides against genetically characterized isolates of Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis. Journal of Antimicrobial ChemoTherapy 50(1): 145-148, 2002

In vitro susceptibility of respiratory isolates of Streptococcus pneumoniae and Streptococcus pyogenes to telithromycin and 11 other antimicrobial agents: Turkish results of e-BASKETT-II surveillance study. Mikrobiyoloji Bulteni 41(1): 1-9, 2007

In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities. Clinical Microbiology and Infection 9(7): 704-707, 2003

Activity of telithromycin against erythromycin-susceptible and resistant isolates of Streptococcus pneumoniae and S pyogenes from Austria. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 176, 2000

Activity of telithromycin against isolates of Streptococcus pneumoniae and Streptococcus pyogenes collected from pediatric patients in Austria. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 191, 2001

Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae. Journal of Antimicrobial ChemoTherapy 59(6): 1171-1176, 2007

PROTEKT USY4: Activity of telithromycin against isolates of Streptococcus pneumoniae, Streptococcus pyogenes, and Haemophilus influenzae from across the USA in 2003-2004. 2005

Activity of telithromycin against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from pediatric patients in Great Britain Ireland. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 167, 2002

In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children. International Journal of Antimicrobial Agents 18(6): 531-535, 2001

In vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae and Streptococcus agalactiae. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 176, 2000

Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. Journal of ChemoTherapy 19(5): 500-507, 2007

Characterization of erythromycin-resistant Streptococcus pneumoniae in Korea, and In Vitro activity of telithromycin against erythromycin-resistant Streptococcus pneumoniae. Microbial Drug Resistance 11(3): 260-265, 2005